title: Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies.
abstract: The essential features of bipolar affective disorder involve the cyclical occurrence of high (manic or hypomanic episodes) and low mood states. Depressive episodes in both bipolar I and II disorder are more numerous and last for longer duration than either manic or hypomanic episodes. In addition depressive episodes are associated with higher morbidity and mortality. While multiple agents, including all 5 atypical antipsychotics, have demonstrated efficacy and earned US FDA indication for manic phase of bipolar illness, the acute treatment of bipolar depression is less well-studied. The first treatment approved by the US FDA for acute bipolar depression was the combination of the atypical antipsychotic olanzapine and the antidepressant fluoxetine. Recently, quetiapine monotherapy has demonstrated efficacy in the treatment of depressive episodes associated with both bipolar I and II disorder and has earned US FDA indication for the same.
authors.affiliation: Case Western Reserve University (CWRU) School of Medicine. 11400 Euclid Avenue, Cleveland OH, USA. prashant.gajwani@uhhospitals.org
authors.forename: Prashant
authors.initials: P
authors.lastname: Gajwani
authors.forename: David J
authors.initials: DJ
authors.lastname: Muzina
authors.forename: David E
authors.initials: DE
authors.lastname: Kemp
authors.forename: Keming
authors.initials: K
authors.lastname: Gao
authors.forename: Joseph R
authors.initials: JR
authors.lastname: Calabrese